Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Anti-PD-L1 Approved in China for Non-Small Cell Lung Cancer

publication date: Dec 21, 2021

Suzhou CStone Pharma reported its anti-PD-L1 monoclonal antibody was approved for first-line use in non-small cell lung cancer. Cejemly® (sugemalimab) was approved in combination with chemotherapy for treatment-naïve metastatic NSCLC patients with no EGFR or ALK genomic tumor aberrations and in combination with paclitaxel and carboplatin as a first-line treatment for metastatic squamous NSCLC. CStone pointed out that Cejemly is the first PD-L1 approved as a first-line treatment of metastatic non-squamous and squamous NSCLC patients worldwide. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.